Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine, (S)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.62 |
| ▸ | ARG2 | P78540 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine SCHEMBL8581344 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL26327 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL60699 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL3022583 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL3244719 | 0.98 | ODC1 (0.96) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4815 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | ORBUS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | claimed |
| CN-118497132-B | Composition for improving CHO cell yield and regulating sugar type and application thereof | 苏州依科赛生物科技股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118497132-A | Composition for improving CHO cell yield and regulating sugar type and application thereof | 苏州依科赛生物科技股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240218051-A1 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | GENZYME CORPORATION | 2024-07-04 | — | — | US | claimed |
| CN-112481337-B | High mannose glycoform content of regulatory ornithine metabolism to manipulate recombinant proteins | 美国安进公司 | 2024-06-25 | — | — | CN | claimed |
| US-20240165063-A1 | METHODS FOR TREATING NEUROBLASTOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | claimed |
| WO-2024067670-A1 | ANTIBODY AND CONJUGATE | 苏州智核生物医药科技有限公司 | 2024-04-04 | — | — | WO | claimed |
| CN-115531555-B | Application of mannose-modified nanoparticles in preparation of medicines for treating osteosarcoma | 上海市第一人民医院 | 2024-02-09 | — | — | CN | claimed |
| US-4818770-A | APPLYING ALPHA-DIFLUOROMETHYL-ORNITHINE INHIBITOR | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH (US) | 1989-04-04 | — | — | US | claimed |
| CN-88100500-A | NOVEL POLYAMINE DERIVATIVES | — | 1988-09-07 | — | — | CN | claimed |
| EP-0277635-A2 | Novel polyamine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-10 | — | — | EP | claimed |
| US-4760091-A | Applying fungicidally effective amount of an ornithine decarboxylase inhibitor | THE DOW CHEMICAL COMPANY (US) | 1988-07-26 | — | — | US | claimed |
| EP-0248217-A2 | Use of ornithine decarboxylase inhibitor for preparing a medicament for use in the treatment, in conjuction with LAK cells and interleukin-2, of tumors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-12-09 | — | — | EP | claimed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | claimed |
| EP-0162413-A2 | Polyamine for use as a medicine in the treatment of neoplasms | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4499072-A | Process for treating diseases with ODC inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-02-12 | — | — | US | claimed |
| US-4433051-A | Derivatives of α-difluoromethylornithine useful in analysis | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IS) | 1984-02-21 | — | — | US | claimed |
| US-4207315-A | Process for treating proliferative skin diseases using certain diamino compounds | UNIVERSITY PATENTS, INC. (US) | 1980-06-10 | — | — | US | claimed |